713,434 Shares in Abivax SA Sponsored ADR $ABVX Bought by Fairmount Funds Management LLC

Key Points

• Fairmount Funds Management acquired a new Q3 position of 713,434 shares of Abivax (NASDAQ:ABVX) valued at about $60.6 million, making the holding 5.4% of Fairmount’s portfolio and roughly 0.92% ownership of Abivax.
• Analysts remain generally positive with an average rating of "Moderate Buy" and an average target price of $134.75 (consensus includes 1 Strong Buy, 11 Buy and 1 Sell).
• Abivax is a clinical-stage biopharma (market cap ~$9.13 billion) with a 52-week range of $4.77–$148.83, currently unprofitable (negative EPS, P/E -27.63) and its lead asset is obefazimod (ABX464) for ulcerative colitis.

Fairmount Funds Management LLC acquired a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 713,434 shares of the company's stock, valued at approximately $60,571,000. Abivax makes up 5.4% of Fairmount Funds Management LLC's portfolio, making the stock its 12th biggest holding. Fairmount Funds Management LLC owned about 0.92% of Abivax as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its position in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after purchasing an additional 369 shares in the last quarter. First Horizon Corp purchased a new position in shares of Abivax in the 3rd quarter valued at about $36,000. Bank of America Corp DE lifted its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new stake in shares of Abivax in the third quarter valued at about $52,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after buying an additional 2,595 shares in the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Citigroup restated a "market outperform" rating on shares of Abivax in a research report on Thursday, January 8th. BTIG Research reiterated a "buy" rating and set a $150.00 price target on shares of Abivax in a research report on Wednesday, February 25th. Wedbush assumed coverage on Abivax in a research note on Tuesday, February 24th. They set an "outperform" rating and a $110.00 price target on the stock. Truist Financial set a $140.00 price objective on Abivax in a research note on Monday, November 24th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $134.75.

Abivax Stock Performance

Abivax stock opened at $115.50 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. Abivax SA Sponsored ADR has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The stock has a fifty day moving average of $118.99 and a two-hundred day moving average of $109.10. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -27.63 and a beta of 1.01.

Abivax (NASDAQ:ABVX - Get Free Report) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. On average, analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.